Skip to content

Author

Gong Dong

We have 2 of 5 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-World Safety Profile of Mirvetuximab Soravtansine: A Population-Based Pharmacovigilance Study Leveraging FAERS and EudraVigilance Databases.

PURPOSE Mirvetuximab soravtansine (MIRV) is the first FDA-approved antibody-drug conjugate targeting folate receptor-α (FRα)-positive platinum-resistant ovarian cancer. Despite its clinical adoption, comprehensive post-marketing real-world evidence regarding its safety profile remains limited. This study aimed to syste...

Zhi-Wei Cui, Ping Song, De Xie et al. · 0 citations
Jul 2026

PNPT1-induced mitochondrial dysfunction drives osteoclast activation via post-transcriptional Nrf2 suppression and lipid peroxidation signaling.

By inciting mitochondrial damage, provoking ROS buildup, and decoupling the protective autophagy-Nrf2/xCT axis, PNPT1 promotes osteoclastogenesis, thereby introducing a promising immunopharmacological target for restraining pathological bone resorption.

Cheng-Yan Liu, Xinlin Nie, Fangze Xing et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.